Form 4: SELLAS Life Sciences Director Katherine Bach Kalin Reports Transaction
SEC Form 4
Katherine Bach Kalin, a director at SELLAS Life Sciences Group, Inc., reports the acquisition and disposal of common stock on May 22, 2025.
Summary
- On May 22, 2025, Katherine Bach Kalin, a director of SELLAS Life Sciences Group, Inc., reported a transaction involving the company's common stock.
- Kalin acquired 20,000 shares of common stock at a price of $1.8 per share.
- Following the reported transaction, Kalin directly owns 41,000 shares of SELLAS Life Sciences Group, Inc.
Sentiment
Score: 5
Explanation: This is a neutral report of a stock transaction by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US market and are required by the SEC to provide transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects the director's investment activity in the company.
Key Dates
| Date | Description |
|---|---|
| 05/22/2025 | Date of transaction: acquisition and disposal of common stock. |
Keywords
SELLAS Life Sciences Group, Director, Stock Transaction, Form 4, Beneficial Ownership, Kalin, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.